Human microbiome and metabolic health: An overview of systematic reviews

Abstract

Summary To summarize the microbiome's role in metabolic disorders (insulin resistance, hyperglycemia, type 2 diabetes, obesity, hyperlipidemia, hypertension, nonalcoholic fatty liver disease [NAFLD], and metabolic syndrome), systematic reviews on observational or interventional studies (prebiotics/probiotics/synbiotics/transplant) were searched in MEDLINE and Embase until September 2020. The 87 selected systematic reviews included 57 meta‐analyses. Methodological quality (AMSTAR2) was moderate in 62%, 12% low, and 26% critically low. Observational studies on obesity (10 reviews) reported less gut bacterial diversity with higher Fusobacterium, Lactobacillus reuteri, Bacteroides fragilis, and Staphylococcus aureus, whereas lower Methanobrevibacter, Lactobacillus plantarum, Akkermansia muciniphila, and Bifidobacterium animalis compared with nonobese. For diabetes (n = 1), the same was found for Fusobacterium and A. muciniphila, whereas higher Ruminococcus and lower Faecalibacterium, Roseburia, Bacteroides vulgatus, and several Bifidobacterium spp. For NAFLD (n = 2), lower Firmicutes, Rikenellaceae, Ruminococcaceae, whereas higher Escherichia and Lactobacillus were detected. Discriminating bacteria overlapped between metabolic disorders, those with high abundance being often involved in inflammation, whereas those with low abundance being used as probiotics. Meta‐analyses (n = 54) on interventional studies reported 522 associations: 54% was statistically significant with intermediate effect size and moderate between‐study heterogeneity. Meta‐evidence was highest for probiotics and lowest for fecal transplant. Future avenues include better methodological quality/comparability, testing functional differences, new intervention strategies, and considerating other body habitats and kingdoms.

Kanglaite (Coix Seed Extract) as Adjunctive Therapy in Cancer: Evidence Mapping Overview Based on Systematic Reviews With Meta-Analyses

“…However, the prospective protocol may be not particularly useful, as our research team is very familiar with the overview using the evidence mapping approach (Lu et al, 2021a;Lu et al, 2021b;Lu et al, 2022). Second, similar to other published overviews (Lu et al, 2021a;Michels et al, 2022), only two large bibliographic databases, namely, PubMed and Embase were searched rather than searching other databases, such as the Cochrane Library, which is collected in PubMed, although may have a time lag. Third, only quantitative systematic reviews published in English were included and Chinese papers were excluded.…”

Effects of the Lipid Profile, Type 2 Diabetes and Medication on the Metabolic Syndrome—Associated Gut Microbiome

“…Even though the definition of a healthy microbiome is still missing, diverse medical conditions have been linked to certain microbiota patterns [ 14 ]. An altered microbiota generally characterised by loss of diversity and an enrichment of opportunistic pathogens has been reported for obesity, T2DM, and MetSyn [ 15 ]. In the case of MetSyn, detailed analyses of the microbiome variance depending on the type of comorbidities, and treatment regimens are still needed to improve patient outcomes.…”

The essential roles of FXR in diet and age influenced metabolic changes and liver disease development: a multi-omics study

“…S9), as butyrate-producing bacteria, were reduced in aged WT mice. Age associated reduction of Rikenellaceae was unique for FXR KO mice, the reduced Rikenellaceae is also found in metabolic disorders including NAFLD [55]. FXR KO mice also have a distinct gut microbiota structure in comparison to the WT, and Bacteroidaceae are expanded in FXR KO mice [4].…”